Payment overview · 2025
General Payments
$7,723.85
119 reported records · 29 companies
Healthcare provider profile · identity verified
Anthony Esposito, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · ANNISTON, AL · NPI 1083655187
Verified facts
What the public records show
CMS Open Payments records show Anthony Esposito, MD received $7,723.85 in general payments during 2025 across 119 reported records.
ABBVIE INC. accounted for 75.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Briviact, Fycompa, Nuplazid, Nurtec Odt, Qulipta, Ubrelvy, Valtoco.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ubrelvy by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nuplazid by this doctor in 2024.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FYCOMPA as an associated drug or biological on 3130 records involving 1101 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Fycompa by this doctor in 2024.
Neurelis, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VALTOCO as an associated drug or biological on 16082 records involving 5567 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Valtoco by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Xcopri by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $5,849.91 | 75.7% | 29 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $244.86 | 3.2% | 14 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $173.56 | 2.2% | 10 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $157.70 | 2.0% | 2 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $120.09 | 1.6% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $111.62 | 1.4% | 5 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $101.44 | 1.3% | 5 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $94.98 | 1.2% | 5 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $83.72 | 1.1% | 4 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $80.49 | 1.0% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $73.98 | 1.0% | 4 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $70.89 | 0.9% | 2 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $67.76 | 0.9% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $50.36 | 0.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $50.22 | 0.7% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $48.30 | 0.6% | 2 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$48.16 | 0.6% | 3 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $44.86 | 0.6% | 2 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $37.23 | 0.5% | 2 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$33.16 | 0.4% | 2 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $31.97 | 0.4% | 2 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.87 | 0.3% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $22.40 | 0.3% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $19.43 | 0.2% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $18.02 | 0.2% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $17.31 | 0.2% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.47 | 0.2% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $15.61 | 0.2% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.48 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,250.00 | 2 |
| Food and Beverage | $2,363.25 | 115 |
| Travel and Lodging | $110.60 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $5,634.56 | 18 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $2,943.09 | 13 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $173.56 | 10 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $157.70 | 2 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $140.62 | 10 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $122.26 | 5 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $120.09 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $111.62 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $111.62 | 5 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $101.44 | 5 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $94.98 | 5 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $88.50 | 5 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $87.27 | 7 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $83.72 | 4 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $80.49 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $73.98 | 4 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $50.36 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $50.22 | 3 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $48.16 | 3 | 2025 |
Source payment records
|
|||||
| AVONEX Normalized: avonex |
Biological | Biogen, Inc. | $28.35 | 2 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $25.87 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $22.40 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| ELYXYB - CELECOXIB Normalized: elyxyb celecoxib |
Drug | SCILEX PHARMACEUTICALS INC. | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $13.48 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $11.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Briviact briviact |
2025 | Briviact | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FYCOMPA fycompa |
2025 | Fycompa | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 63 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 72 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VALTOCO valtoco |
2025 | Valtoco | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
72 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FYCOMPA open payments reported associated product |
CMS Open Payments — General Payments 3130 supporting records · 1101 recipient NPIs · example record 1253216846 |
Fycompa · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Neurelis, Inc. Exact reporting entity; no affiliate inference |
2025 | VALTOCO open payments reported associated product |
CMS Open Payments — General Payments 16082 supporting records · 5567 recipient NPIs · example record 1219183925 |
Valtoco · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
63 | 11 |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 400 | 75 |
| Memantine Hcl | Memantine Hcl | 291 | 72 |
| Topiramate | Topiramate | 280 | 59 |
| Clonazepam | Clonazepam | 277 | 44 |
| Rizatriptan | Rizatriptan Benzoate | 246 | 44 |
| Levetiracetam | Levetiracetam | 233 | 47 |
| Pregabalin | Pregabalin | 230 | 39 |
| Lamotrigine | Lamotrigine | 207 | 35 |
| Donepezil Hcl | Donepezil Hcl | 196 | 56 |
| Alprazolam | Alprazolam | 185 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 185 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 136 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 128 | 24 |
| Sumatriptan Succinate | Sumatriptan Succinate | 126 | 27 |
| Promethazine Hcl | Promethazine Hcl | 122 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 118 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 111 | 24 |
| Amlodipine Besylate | Amlodipine Besylate | 106 | 28 |
| Diazepam | Diazepam | 106 | 18 |
| Tramadol Hcl | Tramadol Hcl | 105 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 99 | 21 |
| Phenobarbital | Phenobarbital | 95 | suppressed |
| Levetiracetam Er | Levetiracetam | 93 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 89 | 22 |
| Primidone | Primidone | 87 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 83 | 19 |
| Trazodone Hcl | Trazodone Hcl | 83 | 19 |
| Zonisamide | Zonisamide | 83 | 12 |
| Lorazepam | Lorazepam | 79 | 19 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 76 | 21 |
| Carbamazepine Er | Carbamazepine | 75 | 12 |
| Lacosamide | Lacosamide | 75 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 72 | 14 |
| Qulipta | Atogepant | 72 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 18 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 71 | 12 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 68 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 68 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 67 | 13 |
| Aimovig Autoinjector | Erenumab-Aooe | 63 | 12 |
| Nurtec Odt | Rimegepant Sulfate | 63 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 58 | 11 |
| Sertraline Hcl | Sertraline Hcl | 58 | 12 |
| Carbamazepine | Carbamazepine | 53 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 52 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 50 | 14 |
| Meloxicam | Meloxicam | 50 | 18 |
| Oxcarbazepine | Oxcarbazepine | 50 | 12 |
| Baclofen | Baclofen | 48 | 15 |
| Propranolol Hcl Er | Propranolol Hcl | 47 | 14 |
| Buspirone Hcl | Buspirone Hcl | 45 | suppressed |
| Ondansetron Odt | Ondansetron | 45 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | suppressed |
| Ubrelvy | Ubrogepant | 44 | suppressed |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 43 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 11 |
| Eszopiclone | Eszopiclone | 39 | 12 |
| Austedo | Deutetrabenazine | 37 | suppressed |
| Xcopri | Cenobamate | 37 | suppressed |
| Atenolol | Atenolol | 35 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 35 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 35 | suppressed |
| Topamax | Topiramate | 32 | suppressed |
| Vimpat | Lacosamide | 32 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 31 | suppressed |
| Methocarbamol | Methocarbamol | 29 | 12 |
| Rasagiline Mesylate | Rasagiline Mesylate | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | 11 |
| Lisinopril | Lisinopril | 27 | suppressed |
| Austedo Xr | Deutetrabenazine | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 25 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Xtampza Er | Oxycodone Myristate | 24 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 23 | suppressed |
| Omeprazole | Omeprazole | 23 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Lamictal | Lamotrigine | 21 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 20 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 20 | suppressed |
| Amantadine | Amantadine Hcl | 19 | suppressed |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Armodafinil | Armodafinil | 18 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 18 | suppressed |
| Belsomra | Suvorexant | 18 | suppressed |
| Losartan Potassium | Losartan Potassium | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 15 |
| Prednisone | Prednisone | 18 | suppressed |
| Azathioprine | Azathioprine | 17 | suppressed |
| Betaseron | Interferon Beta-1b | 17 | suppressed |
| Fycompa | Perampanel | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Valtoco | Diazepam | 16 | suppressed |
| Phenytoin | Phenytoin | 15 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 14 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Avonex (4 Pack) | Interferon Beta-1a | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Buprenorphine | Buprenorphine | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Levocarnitine | Levocarnitine | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Topiramate Er | Topiramate | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Zolmitriptan | Zolmitriptan | 13 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 12 | suppressed |
| Briviact | Brivaracetam | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 12 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 11 | suppressed |
| Glatopa | Glatiramer Acetate | 11 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $7,723.85 · 119 records | ABBVIE INC. | AMVUTTRA, AVONEX, BOTOX, BRIUMVI, Briviact, CREXONT, ELYXYB - CELECOXIB, FYCOMPA, Gamunex-C, Hizentra, INGREZZA, KESIMPTA, KISUNLA, LEQEMBI, NUPLAZID, NURTEC ODT, Ocrevus Zunovo, PURIFIED CORTROPHIN GEL, QULIPTA, TYSABRI, UBRELVY, UPLIZNA, VALTOCO, VRAYLAR, VUMERITY, VYALEV, VYEPTI, VYVGART HYTRULO, ZAVZPRET, ZEPOSIA, ZTLido | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Briviact play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error